CClinicalTrials.gg
TerminatedNCT03329222Updated Sep 10, 2018

An Infant Formula Trial on Dietary Management of Infantile Colic

An interventional study of Specific hydrolysed proteins and Standard cow's milk with prebiotics mixture in Infantile Colic, sponsored by Danone Asia Pacific Holdings Pte, Ltd.. Terminated at 2 sites in 2 countries. Open to participants aged 21 Days to 56 Days. Per ClinicalTrials.gov, last updated 2018-09-10.

Sponsored by Danone Asia Pacific Holdings Pte, Ltd. · Not applicable, Interventional, and Other

Why this study was terminated
slow recruitment
Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
21 Days to 56 Days
Sex
All
01

Study summary

A randomised, double blind, controlled, multi-centre study to assess the efficacy of an infant formula in the dietary management of infantile colic.

Read the detailed description

A randomised, double blind, controlled, multi-centre study to assess the efficacy of an infant formula in the dietary management of infantile colic.

The hypothesis of the study is that the test product, compared to the control formula, will reduce the crying time in infants with infantile colic.

The various time points of the outcome are:

V1 (screening : Day -5 to day 0); V2 ( Randomization: Day 0); V3 (Day 7); V4 (Day 21); Phone Call (Day 28); V5 (End -intervention: Day 42); V6 (Day 56)

02

Conditions studied

  • Infantile Colic

Browse trials for

03

Who can participate

Ages eligible
21 Days to 56 Days
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Infants aged 21-56 days (both inclusive);
  2. Gestation age 37-42 weeks;
  3. Normal birth weight for gestational age and gender
  4. 5-minute APGAR score >7;
  5. Diagnosed with infantile colic ;
  6. Fully formula fed for at least 7 days before randomisation;
  7. Written informed consent from the parent and/or legal representative.

Exclusion criteria

Exclusion Criteria:

  1. Any plausible cause of inconsolable crying as judged by the investigator;
  2. Presence of non-functional vomiting or failure to thrive;
  3. Presence of any congenital defects in the gastrointestinal system or other defects preventing oral nutrition;
  4. Congenital condition and/or previous or current illness/infection and (or) medication use that could interfere with the main study outcomes;
  5. Known cow's milk protein allergy, lactose intolerance, or galactosaemia; including presence of any allergic manifestations;
  6. Received any special formula (e.g. lactose-free, hydrolysed protein);
  7. Received any of the following products/medication within 7 days before randomisation:

    1. Probiotics
    2. Systemic antibiotics
    3. Prokinetics
    4. Proton pump inhibitors
  8. Twins or triplets or other infant(s) \<6 months of age living in the same household;
  9. Incapability of the parent(s) to comply with the study protocol or investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements;
  10. Current participation in another clinical study involving investigational or marketed products.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Intervention group

    An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose

    Other: Specific hydrolysed proteins

  • Active comparator
    Control group

    Standard cow's milk with prebiotics mixture

    Other: Standard cow's milk with prebiotics mixture

Interventions

  • OtherSpecific hydrolysed proteins

    An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose

  • OtherStandard cow's milk with prebiotics mixture

    Standard cow's milk with prebiotics mixture

05

What researchers measure

Primary outcomes

  1. Daily inconsolable crying time using data recorded on subject's diaries

    Daily inconsolable crying time over 6 weeks

    Time frame: 6 weeks

Secondary outcomes

  1. Daily crying time using data recorded on subject's diaries

    Daily crying time over 6 weeks of intervention

    Time frame: 6 weeks

  2. Daily fussing time using data recorded on subject's diaries

    Daily fussing time over 6 weeks of intervention

    Time frame: 6 weeks

  3. Daily inconsolable fussing time using data recorded on subject's diaries

    Daily inconsolable fussing time over 6 weeks of intervention

    Time frame: 6 weeks

  4. Daily stool frequency using data recorded on subject's diaries

    Daily stool frequency over 6 weeks of intervention

    Time frame: 6 weeks

  5. Daily stool consistency using data recorded on subject's diaries

    Daily stool consistency over 6 weeks of intervention

    Time frame: 6 weeks

  6. The frequency of subject's GI symptoms of digestion in the 7-day period prior to the visit using the Infant gastrointestinal symptoms questionnaire

    Gastrointestinal symptoms using the Infant gastrointestinal symptoms questionnaire during the 6-week intervention period

    Time frame: 6 weeks

  7. The intensity of subject's GI symptoms of digestion in the 7-day period prior to the visit using the Infant gastrointestinal symptoms questionnaire

    Gastrointestinal symptoms using the Infant gastrointestinal symptoms questionnaire during the 6-week intervention period

    Time frame: 6 weeks

06

Study locations

2 sites
  • National University Hospital, Singapore
    Singapore, 119228, Singapore
  • Phramongkutklao Hospital
    Bangkok, Thailand
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03329222
Lead sponsor
Danone Asia Pacific Holdings Pte, Ltd.
Collaborators
National University Hospital, Singapore, Phramongkutklao College of Medicine and Hospital, Maharaj Nakorn Chiang Mai Hospital
Responsible party
Sponsor
First posted
Nov 1, 2017
Start date
Oct 27, 2017
Primary completion
Jul 3, 2018
Completion
Jul 3, 2018
Last update
Sep 10, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion